Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals已在多達66名健康志願者和補體介導的腎臟疾病患者中爲該公司研究中的RNA干擾治療藥物ARO-CFB的1/2A期試驗的第一批受試者給藥
Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals已在多達66名健康志願者和補體介導的腎臟疾病患者中爲該公司研究中的RNA干擾治療藥物ARO-CFB的1/2A期試驗的第一批受試者給藥
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。